Literature DB >> 21485837

Lipid drug conjugate (LDC) nanoparticles as autolymphotrophs for oral delivery of methotrexate.

Rishi Paliwal1, Shivani Rai, Suresh P Vyas.   

Abstract

The objective of the study was to develop lipid drug conjugate nanoparticles (LDC-NPs) of anticancer drug methotrexate (MTX) for oral delivery that faces problems of low and variable bioavailability. The MTX loaded LDC-NPs significantly enhanced bioavailability and reduced MTX associated gastrointestinal toxicity even in higher doses recommended for anticancer therapy.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21485837     DOI： 10.1166/jbn.2011.1235

Source DB:  PubMed          Journal:  J Biomed Nanotechnol        ISSN： 1550-7033            Impact factor:   4.099


  4 in total

1.  MDR1 and OAT1/OAT3 mediate the drug-drug interaction between puerarin and methotrexate.

Authors:  Qi Liu; Changyuan Wang; Qiang Meng; Xiaokui Huo; Huijun Sun; Jinyong Peng; Xiaochi Ma; Pengyuan Sun; Kexin Liu
Journal:  Pharm Res       Date:  2013-11-16       Impact factor: 4.200

2.  Convection-enhanced delivery of methotrexate-loaded maghemite nanoparticles.

Authors:  Enav Corem-Salkmon; Zvi Ram; Dianne Daniels; Benny Perlstein; David Last; Sharona Salomon; Gregory Tamar; Ran Shneor; David Guez; Shlomo Margel; Yael Mardor
Journal:  Int J Nanomedicine       Date:  2011-08-03

3.  Preparation and assessment of chitosan-coated superparamagnetic Fe3O4 nanoparticles for controlled delivery of methotrexate.

Authors:  S Mohammadi-Samani; R Miri; M Salmanpour; N Khalighian; S Sotoudeh; N Erfani
Journal:  Res Pharm Sci       Date:  2013-01

Review 4.  Lipid nanoparticles as carriers for RNAi against viral infections: current status and future perspectives.

Authors:  Josune Torrecilla; Alicia Rodríguez-Gascón; María Ángeles Solinís; Ana del Pozo-Rodríguez
Journal:  Biomed Res Int       Date:  2014-08-12       Impact factor: 3.411
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.